Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain.
Antipsychotic-induced weight gain has important effects on treatment compliance and long-term health. Several reports have indicated that a -2548A/G single-nucleotide polymorphism (SNP) of the leptin gene is associated with antipsychotic-induced weight gain. We hypothesized that there is a similar relationship between the -2548A/G SNP and olanzapine-induced weight gain. A total of 74 Korean schizophrenic patients were examined. Their weight was measured before starting olanzapine and after long-term treatment lasting for at least 3 months. The weight gain was significantly higher for patients with the AG genotype than for those with the AA genotype (p=0.029). Analysis of covariance also showed the difference of weight gain was still significant when adjusted for sex and treatment duration (p=0.046). This finding supports the presence of a relationship between the -2548A/G SNP of the leptin gene and weight gain in Korean schizophrenic patients receiving olanzapine treatment.
Kang
Seung-Gul
SG
Department of Psychiatry, Korea University College of Medicine, Seoul, South Korea.
Lee
Heon-Jeong
HJ
Park
Young-Min
YM
Choi
Jung-Eun
JE
Han
Changsu
C
Kim
Yong-Ku
YK
Kim
Seung-Hyun
SH
Lee
Min-Soo
MS
Joe
Sook-Haeng
SH
Jung
In-Kwa
IK
Kim
Leen
L
D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D015992:Body Mass Index; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D007723:Korea; D020738:Leptin / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology; D015430:Weight Gain / Q000187:drug effects* / Q000235:genetics